Breast Cancer Clinical Trial

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

Summary

This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have progressive disease. The investigators hypothesize that SBRT directed at metastatic breast cancer lesions will result in a systemic anti-tumor immune system response. This amplified and directed immune response could result in anti-tumor responses.

View Full Description

Full Description

Patients will receive one of three different doses of SBRT depending on which cohort they are in. The doses are:

Cohort 1: 15 Gy (central tumors 10 Gy); Cohort 2: 20 Gy (central tumors 15 Gy); Cohort 3: 20 Gy x 2 (central tumors 15 Gy x 2).

In addition, all patients will receive three doses of MEDI6469. MEDI6469 is administered at 0.4 mg/kg IV over 60 minutes using in-line filter on Days 1, 3, and 5.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed breast cancer with clinical evidence of stage 4 disease
Measurable disease and at least one lesion in either liver or lung that is amenable to stereotactic body radiation
One site of disease that will not receive radiation
Patients with hormone receptor positive breast cancer must have received prior anti-hormonal therapy for metastatic disease and have progressed and patients with hormone receptor negative breast cancer must have received at least one prior chemotherapy regimen and progressed.
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
Women of childbearing potential must have a negative pregnancy test on the day treatment starts and must avoid becoming pregnant while on treatment. Men must avoid fathering a child while on treatment.
Patients must have blood test results within pre-specified range
No active bleeding
No clinical coagulopathy (INR <1.5, PT <16 seconds, PTT < 38 seconds) within 28 days
Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

Active infection requiring systemic antibiotics.
Active autoimmune disease as defined by the autoimmune disease assessment tool.
Previous treatment with mouse monoclonal antibodies
At least 28 days since prior chemotherapy or monoclonal antibody therapy (trastuzumab or bevacizumab). Patients who have been on hormonal therapy can continue on therapy at the discretion of the investigator. Bisphosphonate therapy is acceptable during study participation.
Diagnosis of a solid tumor malignancy (excluding non-melanoma skin cancer) within 3 years of enrollment.
Need for chronic maintenance oral steroids.
Active brain metastatic disease. Treated brain metastases with surgery, gamma-knife radiosurgery or radiation and stable for at least 4 weeks and off steroids are eligible.
No metastatic site amenable to SBRT
Pregnant or lactating women, as treatment involves risks to the embryo or fetus.
Other medical or psychiatric conditions that in the opinion of the Principal Investigator would preclude safe participation in protocol.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT01862900

Recruitment Status:

Completed

Sponsor:

Providence Health & Services

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Portland Providence Medical Center
Portland Oregon, 97213, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

14

Study ID:

NCT01862900

Recruitment Status:

Completed

Sponsor:


Providence Health & Services

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider